Global Proton Pump Inhibitors Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Gastrointesti

Comments ยท 15 Views

The global Proton Pump Inhibitors (PPIs) market is projected to reach a value of US$2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% over the forecast period of 2022-2030, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:
Proton pump inhibitors are a class of drugs used to reduce the production of gastric acid, thereby treating conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. These drugs work by inhibiting the enzyme called gastric proton pump responsible for acid secretion in the stomach. Proton pump inhibitors are widely prescribed and available over the counter. They provide relief from symptoms such as heartburn, indigestion, and acidity.

B) Market Dynamics:
The global proton pump inhibitors market is driven by two major factors. Firstly, with the increasing prevalence of gastrointestinal disorders such as GERD and peptic ulcers, there is a growing demand for effective and long-lasting treatment options. Proton pump inhibitors provide quick relief from symptoms and help in the healing of damaged tissues. Secondly, the rising geriatric population is also contributing to the market growth. Elderly individuals are more prone to gastrointestinal disorders and are frequently prescribed proton pump inhibitors for their management.

For instance, according to the World Health Organization (WHO), the global population aged 60 years and above is expected to reach 2 billion by 2050, up from 900 million in 2015. This demographic shift is expected to increase the demand for proton pump inhibitors, driving market growth.

C) SWOT Analysis:
Strengths:
1. Effective acid reduction: Proton pump inhibitors are highly effective in reducing gastric acid production, providing relief from acid-related disorders.
2. Wide availability: Proton pump inhibitors are widely available as both prescription and over-the-counter medications, making them easily accessible to patients.

Weaknesses:
1. Long-term use risks: Prolonged use of proton pump inhibitors can lead to potential side effects such as fractures, kidney damage, and Clostridium difficile infection.
2. Cost: Proton pump inhibitors can be expensive for patients, especially for those without insurance coverage, limiting their accessibility.

Opportunities:
1. Untapped emerging markets: There is significant potential for market growth in emerging economies with a large population base and increasing healthcare expenditure.
2. Development of novel formulations: Ongoing research and development activities to develop new formulations of proton pump inhibitors can open up new avenues for market players.

Threats:
1. Generic competition: The patent expiry of major proton pump inhibitors has led to the entry of generic drugs, which may pose a threat to the market share of branded products.
2. Adverse effects: Increasing concerns regarding the long-term use of proton pump inhibitors and their association with adverse effects might impact market growth.

D) Key Takeaways:
- The global Proton Pump Inhibitors Market is expected to witness high growth, exhibiting a CAGR of 4.30% over the forecast period.
- North America is expected to dominate the market, driven by the high prevalence of gastrointestinal disorders and well-established healthcare infrastructure.
- Key players operating in the global proton pump inhibitors market include AstraZeneca PLC, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, and Eisai Pharmaceuticals India Pvt. Ltd. These players focus on strategies such as product launches, collaborations, and acquisitions to maintain their market presence and gain a competitive edge.

In conclusion, the global proton pump inhibitors market is poised for significant growth due to the increasing prevalence of gastrointestinal disorders and the growing geriatric population. However, the market faces challenges such as the potential side effects of long-term use and generic competition. Expanding into untapped emerging markets and developing novel formulations present opportunities for market players to stay ahead in this competitive landscape.

disclaimer
Comments